Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tIRV + bivalent BNT162b2
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
TIRV-BioNTech SE-COVID-19-Influenza refers to a combination vaccine candidate consisting of a trivalent influenza mRNA vaccine (tIRV) and a bivalent COVID-19 mRNA vaccine (BNT162b2). Developed by BioNTech in collaboration with Pfizer, this candidate utilizes nucleoside-modified messenger RNA (modRNA) technology encapsulated in lipid nanoparticles (LNPs). The COVID-19 component is a bivalent vaccine encoding the spike protein of the ancestral SARS-CoV-2 strain and the Omicron BA.4/BA.5 variants. The trivalent influenza component (tIRV) is designed to encode hemagglutinin (HA) proteins from three influenza strains selected for the relevant season. The vaccine is administered via intramuscular injection and is intended to provide simultaneous protection against both COVID-19 and seasonal influenza, potentially simplifying immunization schedules.
- Other names
- trivalent influenza vaccine/bivalent BNT162b2BioNTech COVID-19-Influenza Combination Vaccine
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on tIRV + bivalent BNT162b2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tIRV + bivalent BNT162b2.